How Trump’s vaccine plan would be a logistical nightmare for parents and drug manufacturers
Public health experts have been quick to condemn an executive order from President Donald Trump aimed at upending childhood vaccinations in the U.S., but the biggest obstacles may be the unprecedented financial and logistical challenges it would impose on parents, health providers and drugmakers. Monday’s announcement by the Republican president calls for separating combination shots — including…
President Donald Trump's recent executive order aims to disrupt childhood vaccinations in the United States, but public health experts have quickly denounced the plan. A key part of the order calls for separating combination vaccines, such as the measles, mumps, and rubella (MMR) shot, into individual injections. This change would require parents to visit pediatricians more frequently and drug manufacturers to revive long-unmarketed vaccines, build new manufacturing plants, and conduct costly studies to prove safety and efficacy.
Public health experts argue that combination vaccines increase the likelihood of children being fully protected from infectious diseases before starting school, and there is no scientific basis for changing course. The order is not legally binding, and drug companies have shown little interest in developing individual versions of vaccines they already sell in combination shots.
Written by urgent.news from Fast Company's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Trump's Vax Order Hands Some MAHA Voters a Win, but Gives Democrats an Attack Line medpagetoday.com
- WHO says Trump's vaccine overhaul goes against 'decades of evidence' lemonde.fr
- Trump's vaccine order hands some MAHA voters a win. It also gives Democrats an attack line pbs.org
- Trump’s vaccine order hands some MAHA voters a win. It also gives Democrats an attack line winnipegfreepress.com
